伊维菌素在COVID-19的临床应用析论  

The Clinical Application of Ivermectin in COVID-19

作　　者：车土玲 蓝萍 余春森 苏裕盛 

机构地区：[1]宁德师范学院医学院,福建 宁德 [2]宁德师范学院毒物与药物毒理学重点研究室,福建 宁德

出　　处：《自然科学》2023年第2期176-182,共7页Open Journal of Nature Science

摘　　要：伊维菌素(Ivermectin, IVM)是美国食品药品管理局(Food and Drug Administration, FDA)批准的广谱抗寄生虫药,已证明对多种DNA和RNA病毒具有抗病毒活性,包括SARS-CoV-2,加上成本低廉、可用性强、耐受性和安全性良好,在COVID-19的临床应用中极具潜力。越来越多证据表明IVM可用抗SARS-CoV-2病毒,但将IVM纳入COVID-19管理的最终呼吁仍然没有定论。因为FDA只评估了IVM在特定动物物种中的安全性和有效性,且IVM动物性药物会对人造成严重伤害。WHO认为IVM治疗COVID-19患者方面尚无定论,IVM在COVID-19中的有效性仍然存在不确定性,其中许多研究没有发现IVM对结局有效。展望未来,IVM或许有望和其他COVID-19治疗方法提供更明确的答案,但现阶段IVM治疗COVID-19不确定的风险仍在,建议不要使用IVM来预防或治疗COVID-19。Ivermectin (IVM) is a broad-spectrum antiparasitic drug approved by the Food and Drug Administration (FDA) that has shown antiviral activity against a variety of DNA and RNA viruses, including SARS-CoV-2;combined with low cost, strong availability, good tolerance and safety, it has great potential for clinical application of COVID-19. More and more evidence suggests that IVM may be used in COVID-19. But the final call to incorporate IVM into COVID-19 management remains inconclusive. Because the FDA has only evaluated the safety and efficacy of IVM in specific animal species, animal-based IVM drugs can cause serious harm to humans. In addition, WHO believes that IVM treatment of patients with COVID-19 is inconclusive, the effectiveness of IVM in COVID-19 is still uncertain, and many of these studies have not found IVM effective for many outcomes. Looking ahead, IVM may be expected to provide a more specific answer to the other COVID-19 treatment, but the risk of the IVM treatment of COVID-19 at this stage is still there, and it is recommended that IVM should not be used to prevent or treat COVID-19.

关 键 词：伊维菌素 IVM COVID-19 

分 类 号：R71[医药卫生—妇产科学]